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Background: A number of neurodevelopmental syndromes are caused by mutations in genes encoding proteins
that normally function in epigenetic regulation. Identification of epigenetic alterations occurring in these disorders
could shed light on molecular pathways relevant to neurodevelopment.
Results: Using a genome-wide approach, we identified genes with significant loss of DNA methylation in blood of
males with intellectual disability and mutations in the X-linked KDM5C gene, encoding a histone H3 lysine 4
demethylase, in comparison to age/sex matched controls. Loss of DNA methylation in such individuals is consistent
with known interactions between DNA methylation and H3 lysine 4 methylation. Further, loss of DNA methylation
at the promoters of the three top candidate genes FBXL5, SCMH1, CACYBP was not observed in more than 900
population controls. We also found that DNA methylation at these three genes in blood correlated with dosage of
KDM5C and its Y-linked homologue KDM5D. In addition, parallel sex-specific DNA methylation profiles in brain
samples from control males and females were observed at FBXL5 and CACYBP.
Conclusions: We have, for the first time, identified epigenetic alterations in patient samples carrying a mutation in
a gene involved in the regulation of histone modifications. These data support the concept that DNA methylation
and H3 lysine 4 methylation are functionally interdependent. The data provide new insights into the molecular
pathogenesis of intellectual disability. Further, our data suggest that some DNA methylation marks identified in
blood can serve as biomarkers of epigenetic status in the brain.
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distribution, and reproduction in any mediumMutations in the KDM5C gene (MIM No: 314690) were
first described as causing X-linked intellectual disability
(XLID) in 2005 [3]. To date, 21 different KDM5C muta-
tions have been identified in XLID patients. The preva-
lence of KDM5C mutations in patients with XLID is
estimated to be ~3% [3-10]. The clinical features most
consistently reported in males with mutations include mild
to severe intellectual disability (ID), epilepsy, short stature,
hyperreflexia, aggressive behavior and microcephaly. In
addition, a mutation in KDM5C was identified in one male
case of autism [11]. Female mutation carriers are usually
unaffected but sometimes demonstrate mild ID or learn-
ing difficulties [7].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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KDM5 family of four proteins, KDM5A/B/C and D.
KDM5A/C/D demethylate tri- and di-methylated forms
of H3K4, whereas KDM5B is capable of demethylating
all three forms (tri-, di-, and mono) of H3K4 methyla-
tion [12,13]. The KDM5C protein contains several con-
served functional domains, including the Bright/ARID
DNA binding domain; the catalytic JmjC domain; the
JmjN domain responsible for protein stability; the zinc
finger-C5HC2 domain; and two PHD domains, respon-
sible for histone binding [14] (Figure 1). Mutations lead-
ing to XLID have been found in most of the functional
domains of this protein [15]. KDM5C is ubiquitously
expressed in almost all human tissues including white
blood cells, with the highest levels of expression found
in the brain and in skeletal muscle [3,15].
A significant effort has been invested in elucidating
the role of KDM5C mutations in the ID phenotype. In
zebrafish, downregulation of KDM5C leads to an in-
crease in neuronal cell death and a decrease in total den-
dritic length [13]. Chromatin immune precipitation
(ChIP) of HeLa cells revealed that KDM5C co-localizes
with a transcriptional repressor REST, in the promoters
of a subset of REST target genes, suggesting that loss of
KDM5C activity impairs REST-mediated neuronal gene
regulation [16]. ChIP-sequencing of a panel of chroma-
tin remodeling proteins in the leukemia cell line K562
had shown that KDM5C along with other transcriptional
repressors binds to a wide range of promoters, including
those that are active, competent, and repressed [17]. The
specific molecular mechanism by which loss of function
of KDM5C causes impairment in neuronal development
is not understood, but epigenetic deregulation is pre-
sumed to play an important role.
The KDM5C protein is likely to play a role not only in
ID but also in sex-specific differences in brain function.
The X-linked human KDM5C and its mouse ortholog
Kdm5c escape X–inactivation [18,19]; and, not surpris-
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Figure 1 Schematic diagram of the human KDM5C protein. The diagra
well as the p.R1546Q variant of unknown clinical significance.compared to XY males in mouse adult brain [20]. This
difference has been shown to be associated with sex
chromosome complement (XX vs. XY), rather than go-
nadal sex of the animals [21]. Interestingly, there is a Y-
linked functional homologue of KDM5C, namely KDM5D,
in both human and mouse. The homologue in murine
neurons, Kdm5d has been shown to be expressed at lower
levels than Kdm5c and is not able to compensate for
Kdm5c differences between females and males [21].
Recent studies suggest there is interplay between his-
tone modifications and DNA methylation [22,23]. This
relationship is bidirectional; histone modifications are
more labile while DNA methylation is more stable [22].
In embryonic development, the formation of histone
marks precedes and guides de novo DNA methylation,
either by recruiting de novo DNA methyltransferase
enzymes (H3K9 methylation) [24], or by protecting DNA
from de novo methylation (H3K4 methylation) [25,26].
We hypothesized that in patients with KDM5C muta-
tions an aberrant increase of H3K4 tri- and di-
methylation leads to decreased DNA methylation at
genomic sites critical for normal neurodevelopment. We
also proposed that the sites exhibiting decreased DNA
methylation due to KDM5C mutation would also exhibit
sexually dimorphic patterns of DNA methylation correlat-
ing with KDM5C and KDM5D dosage in normal females
and males. Since KDM5C escapes X-inactivation [18], we
enriched our sample set by including 47,XXX, 47,XXY
and 45,X (Turner syndrome) individuals. In agreement
with our hypothesis, we identified a significant loss of
DNA methylation at specific genomic loci in blood sam-
ples of male patients carrying KDM5C mutations, suggest-
ing these genes are epigenetic targets of KDM5C. To our
knowledge, this is the first report of significant DNA
methylation alterations in association with a mutation in a
human histone modifying enzyme. Furthermore, we have
shown that some genes with downstream loss of DNA
methylation in individuals with KDM5C mutation also
demonstrate positive correlation for DNA methylationR1481GfsX9
R1546Q
m shows the functional domains and the positions of 5 mutations as
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This study was approved by research ethics boards of
the Greenwood Genetic Center (Greenwood, SC, USA)
and the Hospital for Sick Children (Toronto, ON,
Canada). All research subjects and/or their caregivers
provided informed consent. Blood samples were col-
lected from 10 patients with XLID and confirmed
KDM5C mutations [5], two patients with XLID and
KDM5C sequence variant, 19 unaffected control males
(three unaffected relatives/16 unrelated individuals)
(Additional file 1: Table S1), 13 control females, 11
females with Turner syndrome (45,X karyotype), three
males with 47,XXY karyotype and three females with 47,
XXX karyotype. DNA was extracted from 5 ml of blood
using phenol-chloroform and ethanol precipitation.
Methylation microarray
The HumanMethylation27 BeadChip (Illumina, San
Diego, CA) containing 27,578 individual CpG sites cov-
ering >14,000 genes was used for genome-wide DNA
methylation analysis. Genomic DNA was sodium bisul-
fite converted with the EpiTect Bisulfite Kit according to
the manufacturer’s protocol (Qiagen, Germantown,
MD). Labeling, hybridization and scanning were per-
formed at the Centre for Applied Genomics (TCAG) at
The Hospital for Sick Children, Toronto, Canada. The
methylation status of the interrogated CpG sites was
measured from the intensity values of the methylated
(M) and unmethylated (U) probes, as the ratio of fluor-
escent signals β =Max(M,0)/[Max(M,0) +Max(U,0) + 100].
DNA methylation β values are continuous variables be-
tween 0 (absent methylation) and 1 (completely methy-
lated) representing the ratio of combined locus intensity.
The β values were extracted using the Methylation Module
in Illumina Bead Studio after background normalization.
All samples included in the analysis passed quality control
metrics including bisulfite conversion control intensity
values in green channel >4000 and 99% of probes had
p-values of detection of signal above background <0.01
[27,28]. 6 publically available datasets (accession numbers:
GSE19711, GSE36064, GSE27097, GSE25395, GSE20067,
GSE20236) were used to assess DNA methylation at
FBXL5 (cg02630888), SCMH1 (cg03387723), and CACYBP
(cg16743289) CpG sites. Sex specific DNA methylation
analysis in brain was performed using published dataset
(GEO Accession No: GSE15745) [29]. If the QC informa-
tion was available, only samples with appropriate QC
metrics (BS control intensity values in green channel
>4000 and ≥95% of probes with p-values of detectionof signal above background <0.05) were included in the
analysis.
Statistical analysis
Microarray probes with detection p-value ≥ 0.01 [28],
2,984 cross-reactive probes, and 907 probes overlapping
SNPs in queried CpG [30] were excluded, leaving in total
23,837 sites for downstream statistical analysis. A non-
parametric Mann–Whitney U test was used for group
comparisons. To adjust for multiple comparisons, a
permutation-based method controlling the false discov-
ery proportion (FDP) γ in the data, for a pre-specified
confidence levels α was applied [31]. 1000 random per-
mutations of the mutation labels among the data cases,
while maintaining the sample sizes (10 vs. 19)
were generated. For each permutation Mann–Whitney
U test-based p-values for all CpG sites were ranked
from smallest to largest (from most significant to least
significant). The distribution of the 1000 “best”
permutation-based p-values was used to determine
p-values cut offs for different confidence levels based on
the percentiles of this distribution. The cut off p-values
were used to determine the number of significant CpG
sites at different γ and α level. The Principal Component
Analysis was performed in R statistical package using
median centering of the data as well as with missing-
value imputation to the 10 nearest neighbors.
Bisulfite pyrosequencing
Targeted DNA methylation analysis was performed using
pyrosequencing as described by Tost and Gut [32]. Pyro-
sequencing assays containing two PCR primers and one
sequencing primer were designed to target CpG sites
of interest using PyroMark Assay Design Software
(Qiagen). One of the PCR primers had a universal tag
which annealed to the universal biotinylated primer.
Genomic DNA was sodium bisulfite converted the same
way as for the Illumina microarray and amplified using
Hot-Start Taq-polymerase (Qiagen). Amplicons were
analyzed on a Q24 pyrosequencer (Qiagen) as specified
by the manufacturer; % of methylation was quantified as
the ratio of C to C + T using PyroMark Q24 Software
(Qiagen). Pyrosequencing primers are shown in
Additional file 1: Table S2.
Quantitative real-time RT-PCR
To analyze tissue specific expression of FBXL5, SCMH1
and CACYBP we performed real-time RT-PCR expression
analysis. Total RNA was purchased from Clontech for 8
tissues and 4 brain regions. Lymphoblastoild cell line estab-
lished from control sample C2 RNA was extracted using
RNeasy kit (Qiagen). The cDNA for quantitative real-time
PCR was synthesized using VersoTM cDNA kit (Thermo
Fisher Scientific, Epsom, UK). Mx3005P QPCR System
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Supermix (Bio-Rad, Hercules, CA). Expression of each
gene was determined using the comparative Ct method
and normalized to the expression of the GAPDH house-
keeping gene. Primers sequences are shown in Additional
file 1: Table S2.
Results
Methylation microarray profiling in patients with KDM5C
mutations
To determine whether altered genome-wide DNA
methylation patterns are associated with KDM5C muta-
tions, we performed genome-wide DNA methylation
analyses using the Illumina Infinium HumanMethyla-
tion27 BeadChip array containing 27,578 CpG sites and
covering >14,000 genes in DNA from blood samples of
XLID patients and controls. Our study group was com-
prised of 10 XLID patients from 5 families with 5 differ-
ent KDM5C mutations. Two of these mutations were
frameshift mutations, resulting in premature stop
codons and 3 were missense mutations, predicted to be
damaging by both Polyphen and Sift algorithms [4,5].
The number of affected individuals per family ranged
from one to three. The control group was comprised of
16 age and ethnicity matched normal unrelated males
and three unaffected male relatives (not carrying the
mutation) from the family with the p.V504M mutation.
We also tested two brothers with ID who carried a p.
R1546Q sequence variant of unknown significance
(VUS), predicted to be benign/tolerated by Polyphen
and Sift respectively. During the course of this study,
this KDM5C variant was reclassified as a benign variant,
as it was found in a phenotypically normal maternal
grandfather in another XLID family. Clinical and demo-
graphic information for the XLID patients and controls
and locations of the KDM5C mutations are summarized
in Additional file 1: Table S1 and Figure 1.
Methylation ratios (beta-values) for each of 27,578 CpG
sites were calculated as ratios of methylated CpG to the
sum of methylated and unmethylated CpG. The reliability
of Illumina Infinium data was demonstrated by high cor-
relation (R2 = 0.95-0.99) among samples as well as high
correlation of microarray data with bisulfite pyrosequen-
cing (R2 = 0.77-0.98) (Additional file 2: Figure S1).
Cross-reactive probes and probes overlapping SNPs in
the queried CpGs [30] were excluded, leaving 23,837 sites
for statistical analysis. As a first step in our exploratory
analysis, we used principal component analysis (PCA) and
unsupervised hierarchical clustering to create a high-level
summary of the data for all 23,837 CpG sites. Examination
of these results did not reveal a clear separation between
the mutation cases, VUS cases, unaffected relatives, and
controls (Additional file 2: Figures S2 - S3). This suggests
that if there are DNA methylation differences associatedwith KDM5C mutations they occur at specific loci but not
across all CpG sites analyzed.
To identify the differentially methylated CpG sites, we
compared beta-values between 10 KDM5C mutation
cases and 19 controls using the non-parametric Mann–
Whitney U test. After generating an initial p-value for
each of the 23,837 CpG sites, we observed that as many
as 6,124 sites in a given sample were below the 0.05 sig-
nificance level. To adjust for multiple testing we used a
permutation-based method that estimated false discov-
ery proportion (FDP) levels for pre-specified confidence
levels [31]. We generated 1000 random permutations of
the mutation labels among the data cases, while main-
taining the sample sizes (10 vs. 19), and have identified
significant CpG sites at four FDP levels for three
confidence levels (Additional file 1: Table S3). The top
candidates (53 CpG sites from 51 genes) with the lowest
FDP = 0 and the highest confidence level of 99.5% (un-
adjusted p-values < 2.00e-07) are shown in Additional
file 1: Table S4.
To address the potential effect of relatedness on differ-
ences in DNA methylation and controls we performed
additional analysis including only unrelated individuals
by randomly selecting 5 mutation cases from each of the
five available families and 17 unrelated controls (one
randomly chosen unaffected relative and 16 unrelated
controls). To identify differentially methylated CpG sites,
we performed the Mann–Whitney U test on all 72 pos-
sible combinations of 5 cases vs. 17 controls. We
observed a large degree of consistency between the CpG
sites identified in this analysis (5 unrelated cases vs. 17
unrelated controls) with the CpG sites identified in the
general setting (10 cases vs. 19 controls). For example,
the CpG sites found to be significantly different between
cases and controls across all 72 combinations at 95%
confidence level exactly coincided with the 53 CpG sites
shown in Additional file 1: Table S4 (FDP =0 at 99.5%
confidence in the complete dataset of 10 cases vs. 19
controls).
We further tested if DNA methylation differences at 53
CpG sites with p-values < 2.00e-07 could differentiate
cases either from controls or from the variant of unknown
significance (p.R1546Q). A variety of unsupervised me-
thods including hierarchical clustering (Figure 2), principal
component analysis (Additional file 2: Figure S4), and
K-means and K-median clustering (not shown) were ca-
pable of unambiguously differentiating KDM5C mutation
cases from controls. Two samples, carrying the p.R1546Q
variant at the C-terminal end of the KDM5C protein, con-
sistently showed the same DNA methylation levels as con-
trol samples confirming the benign nature of this variant.
Multiple studies have shown that at some genomic loci
DNA methylation levels could be affected by sequence
polymorphisms in cis and subsequently be heritable
0.0 1.00.5
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Figure 2 Hierarchical unsupervised clustering of 31 study samples. DNA methylation levels at the 53 most significant CpG sites were used
for hierarchical unsupervised clustering. The results show a clear distinction between the 10 KDM5C mutation cases (top part), and the remaining
21 samples (bottom part), which is also indicated by the large distance between the two branches of the dendrogram on the left. DNA
methylation levels corresponding to mutations are generally lower than for the controls. Interestingly, the two cases of variant of unknown
clinical significance (p.R1546Q) have methylation profiles very similar to the 19 controls. Also, mutation cases from the same family do not always
cluster together. The clustering was based on complete linkage and cosine distance metric.
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http://www.biomedcentral.com/1755-8794/6/1[29,33-36]. We determined whether DNA methylation of
the top 53 CpG sites were dependent not only on
KDM5C mutation but also on single nucleotide poly-
morphisms (SNPs). For these analyses, we took advan-
tage of two published datasets that used the same
Illumina HumanMethylation27 microarray platform and
reported a number of methylation quantitative trait loci
(mQTL) in lymphoblastoid cell lines (LCLs) [33,34]. At
these mQTLs DNA methylation depends on genotypes
of single nucleotide polymorphisms (SNPs) located in cis
or trans in relation to CpG. We did not find any mQTLs
at the 53 CpG sites identified in our study, suggesting
that the DNA methylation alterations we observed are
more likely to be associated with KDM5C mutations ra-
ther than other genetic variation that exists between
cases and controls.
In agreement with the prediction of cross-talk between
H3K4 methylation, and DNA methylation, we observed
an over-representation of CpG sites with loss of DNA
methylation versus gain at all levels of FDP and at all
confidence intervals tested (Additional file 1: Table S3, p
< 2.2e-16, Fisher Exact test). All 53 top CpG candidates
with the lowest FDP = 0 and the highest confidence level
of 99.5% (unadjusted p-values < 2.00e-07) exhibited loss
of DNA methylation. The 13 CpGs with the greatest loss
of DNA methylation (delta beta ≤-0.2) are shown in
Table 1. In addition, in the volcano plot where delta betais plotted against p-values, we observed an enrichment
of CpG sites with negative delta beta, reflecting the loss
of DNA methylation. Interestingly, this asymmetry was
limited to CpG islands (Figure 3A). Also, averaging all
microarray probes and comparing cases and controls we
observed a small (<1%) loss of DNA methylation in the
KDM5C mutation group (p = 0.035) also for CpG
islands, but not for non-CpG island probes (Figure 3B).
This genome-wide loss of DNA methylation was
observed only in unique sequences, but not at LINE-1,
the most common non-LTR retrotransposon, comprising
about 17% of the human genome [37] as determined by
pyrosequencing (Additional file 2: Figure S5).
Illumina HumanMethylation27 coverage on average
extends to two CpG sites per gene. Of the 53 most sig-
nificant CpG sites based on permutation analysis, only
two genes C2orf3 (GCFC2) and TSPYL5 had two CpG
sites meeting the permutation p-value cut off. In order
to assess the genomic extent of the DNA methylation
changes for each significant gene we have evaluated
DNA methylation levels, delta beta differences, and
p-values in cases and controls for additional array probes
for the 53 top significant genes. For a majority of the
genes the second probe did not exhibit significant loss of
DNA methylation. Only 8 genes had a second significant
probe with p ≤ 0.05. The absolute delta beta differences
for the second probes were relatively small ≤ 0.05, with
Table 1 Top 13 CpG sites with loss of DNA methylation in KDM5C mutation cases with the lowest false discovery
proportion level =0, the highest confidence level of 99.5% and delta beta ≤ −0.2
Target ID KDM5C AVG Beta Control AVG Beta VUS AVG Beta p-value delta beta delta Z SYMBOL DISTANCE TO TSS
cg02630888 0.41 0.89 0.91 9.98E-08 −0.48 2.03 FBXL5 −807
cg03387723 0.26 0.71 0.73 9.98E-08 −0.45 2.01 SCMH1 −676
cg16743289 0.24 0.52 0.53 9.98E-08 −0.28 2.02 CACYBP −427
cg06736444 0.50 0.78 0.77 9.98E-08 −0.28 1.90 SRRM2 −861
cg22809047 0.31 0.59 0.54 9.98E-08 −0.27 1.91 RPL31 −490
cg19884658 0.55 0.77 0.74 9.98E-08 −0.23 1.98 KLHL21 −1,339
cg14719055 0.20 0.42 0.37 9.98E-08 −0.23 1.92 RBBP7 −1,218
cg16604218 0.09 0.31 0.35 9.98E-08 −0.22 1.84 EIF2B3 −349
cg20318748 0.07 0.29 0.18 9.98E-08 −0.22 1.95 NANP −564
cg03621001 0.46 0.67 0.77 9.98E-08 −0.21 1.91 RAB8A −771
cg00328227 0.08 0.28 0.30 9.98E-08 −0.2 1.95 C1orf59 −177
cg05072008 0.13 0.33 0.37 9.98E-08 −0.2 1.86 FIGNL1 −599
cg03221914 0.50 0.69 0.70 9.98E-08 −0.2 1.82 HIST1H2AJ −813
VUS is p.R1546Q variant of unknown significance, AVG beta is mean beta value for each of three groups, delta beta is differences between mean of KDM5C
mutations cases (N = 10) and controls (N = 19). Delta Z is delta beta divided by standard deviation of combined cases and controls data. All 13 CpG sites were
located within CpG islands.
p = 0.035 NS
A
B
Figure 3 Loss of DNA methylation at CpG islands associated with KDM5C mutations. A) Volcano plot of DNA methylation differences
between controls and KDM5C mutation cases (delta beta, X-axis) versus statistical significance –log10(p) in CpG islands (left) and non-CpG islands
(right). Negative delta beta represents loss and positive delta beta gain of DNA methylation in KDM5C mutation cases. Black lines represent
p-values at three levels of confidence 95% (6.69E-06), 99% (1.07E-06) and 99.5% (2.00e-07). B) Boxplot of the mean methylation of all microarray
probes within CpG islands (left) and non-CpG islands (right) in controls (C) and in KDM5C mutations cases (K).
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http://www.biomedcentral.com/1755-8794/6/1the exception of the STMN1 gene having a delta beta
−0.16 and −0.14 in two CpG sites (Additional file 1:
Table S5). The CpG sites with significant loss of DNA
methylation tended to be located just on the edge of
CpG island several hundred base pairs upstream of TSS.
In contrast, CpG sites without DNA methylation differ-
ences were predominantly unmethylated in both cases
and controls and located a few 100 bp downstream of
TSS (Additional file 1: Table S5, Figure 4 and Additional
file 2: Figures S6 - S9).
Targeted validation by pyrosequencing
We have previously shown that validation of Illumina
HumanMethylation27 CpG methylation by bisulfite
pyrosequencing demonstrates high correlation between
the two methods and methylation determined by Illu-
mina microarray is a good predictor of regional CpG
methylation in CpG islands [38]. To validate the DNA










































Figure 4 Regional DNA methylation in FBXL5 promoter. A) Screenshot
exon1, intron1, CpG island, Illumina microarray probes and pyrosequencing
line (GM12878) and ES cell line (H1 h-ES) (Broad Institute Histone data). B&C
within FBXL5 gene. The Y axis shows DNA methylation levels presented as C
25th and 75th percentiles respectively; the whiskers are within the 1.5 interq
above or below 1.5 IQR. C are controls (N = 19), K are cases with KDM5C mu
methylation upstream of FBXL5 transcription start site as determined by pyr
from the furthest upstream to the transcription start site. Each column is an
(mutation), 2)19 controls (control), and 3) two individuals with the p.R1546Q
overlapping the microarray probe. P-values were determined by Kruskal-Wa
methylation upstream of FBXL5 transcription start site and downstream of p
(pyro 3). The order of CpG sites are shown from the furthest upstream to th
groups of 1) 5 cases with KDM5C mutations (mutation), 2) 5 controls (controfive loci: top three candidates FBXL5 (delta beta =
−0.48), SCMH1 (delta beta = −0.45) and CACYBP (delta
beta = −0.28) with the largest DNA methylation differ-
ences and two loci with smaller differences DYDC1 (delta
beta = −0.1) ZMYND12 (delta beta = −0.08). Using pyrose-
quencing, we validated the direction of the differences for
all 5 loci and observed high correlation DNA methylation
levels between pyrosequencing and Illumina for overlap-
ping CpG sites (R2 ranging from 0.77 to 0.98, Additional
file 2: Figure S1). For FBXL5, SCMH1, CACYBP and
ZMYND2 the assays contained >1 CpG site, and pyrose-
quencing data showed that DNA methylation changes
affected not only the index CpG site from the array but also
multiple adjacent CpGs (Figures 4 and Additional file 2:
Figures S6-S9). The samples carrying the p.R1546Q variant
consistently exhibited the same DNA methylation patterns
as controls. For FBXL5 (8 CpGs) and ZMYND2 (5 CpGs)
all sites tested exhibited DNA methylation differences be-









from the UCSC genome browser showing location of FBXL5 promoter
assays and tracks for H3K4me1 and H3K4me3 in lymphoblastoid cell
) Boxplots of Illumina DNA methylation data for two microrray probes
/C + T and ranging from 0 to 1. The bottom and the top of the box are
uartile range (IQR) of the data, and the circles, are outlier data points
tations (N = 10), V are cases with p.R1546Q sequence variant. D) DNA
osequencing assays 1&2 (pyro1&2). The order of CpG sites are shown
average for each of three groups of 1)10 cases with KDM5C mutations
variant of unknown significance (VUS). The arrow shows the CpG sites
llis test between mutation cases and controls. **** is p <0.0001. E) DNA
yrosequencing assays 1&2 as determined by pyrosequencing assay 3
e transcription start site. Each column is an average for each of two
l). Error bars are standard deviations.
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http://www.biomedcentral.com/1755-8794/6/1Figure S8). For SCMH1 (5 CpGs), the CpG sites more dis-
tant from the TSS exhibited overall higher DNA methyla-
tion in controls and larger differences in DNA methylation
between cases and controls (Additional file 2: Figure S6).
For CACYBP, it was not possible to design a pyrosequen-
cing assay overlapping the Illumina CpG site. Therefore,
we designed an assay covering 2 CpGs ~100 bp upstream
of the Illumina site. In this assay one CpG site exhibited
significant DNA methylation differences between cases and
controls consistent with the difference found on the array
(Additional file 2: Figure S7).
For FBXL5 we designed an additional assay to test
DNA methylation within a CpG island in closer proxim-
ity to the TSS. We found very low overall DNA methyla-
tion levels in both cases and controls (<10%) with no
significant differences. Interestingly, based on ChIP se-
quencing data for histone marks from the Broad
Institute [39], sites that were hypermethylated in
controls and exhibited significant loss of DNA methyla-
tion in KDM5C mutations cases frequently coincided
with enhancer mark H3K4me1 in embryonic stem cell
(ES) and lymphoblastoid cell lines. In contrast, the
mark of active promoters H3K4me3 was shifted
more towards the TSS, where DNA was hypomethylated
(Figure 4, Additional file 2: Figures S6-S9). Thus, it is
possible that sequences exhibiting loss of DNA
methylation in patients with KDM5C mutations are
involved in the regulation of downstream genes through
enhancer activity.
Ubiquitous expression of FBXL5, CACYBP and SCMH1 in
human tissues
We focused the next phases of our downstream analysis
on the three top candidate genes FBXL5, SCMH1 and
CACYBP with the highest delta Z scores (Table 1). Inter-
estingly, the three top CpG sites identified by methyla-
tion array to be significantly hypomethylated in KDM5C
mutations cases are within promoters of genes involved
in ubiquitin-mediated protein degradation [40-43]. FBXL5
is an iron sensing E3 ubiquitin ligase that regulates iron
homeostasis [44]. CACYBP is part of a ubiquitin ligase
complex regulating beta-catenin, which is important for
cell-cell adhesion and transcription regulation through
Wnt-signaling [45]. SCMH1 is part of a polycomb group
complex 1 (PcG1) involved in transcriptional silencing
[46] and proteosomal degradation for the Geminin pro-
tein, important for regulation of replication and main-
tenance of undifferentiated states [42]. Little is known
however about tissue specific expression of these genes in
human. We tested the expression of FBXL5, SCMH1 and
CACYBP in several somatic tissues including brain, kid-
ney, heart, muscle and lymphoblastoid cells, as well as se-
veral brain regions. We observed ubiquitous expression
across tissues and brain regions (0.6-12% of GAPDHexpression level) (Additional file 2: Figure S10), consistent
with the function of these genes in pathways important
for multi-systemic physiological processes.
Loss of DNA methylation associated with KDM5C
mutations is not due to altered blood cell counts
There are no reported blood cell-related phenotypes asso-
ciated with KDM5C mutations [7]. However, white blood
cells consist of functionally distinct cell populations in vary-
ing proportions and it has been shown that at some loci in
different white blood cells DNA methylation patterns can
vary substantially [47]. As we did not have blood cell counts
for either cases or controls in our study, the possibility that
observed DNA methylation differences could be due to dif-
ferences in the proportion in different cell types cannot be
completely ruled out. To test this, we checked DNA methy-
lation levels for the three top candidates FBXL5, SCMH1
and CACYBP using GEO dataset (GSE35069). This dataset
analyzed genome-wide DNA methylation using Illumina
Methylation450 array in DNA from whole blood, peripheral
blood mononuclear cells, and granulocytes, as well as in 7
isolated cell populations (CD4+ T cells, CD8+ T cells,
CD56+ NK cells, CD19+ B cells, CD14+ monocytes, neu-
trophils, and eosinophils) in six healthy males [47]. The
beta values for probes overlapping Illumina27 with signifi-
cant loss of DNA methylation in KDM5C mutations cases
were extracted for analysis. We did not observe differences
between cell types at three CpG sites analyzed at a magni-
tude that could explain loss of DNA methylation in
KDM5C mutations cases (Additional file 2: Figure S11).
For FBXL5, DNA methylation was very uniform across all
cell types, with a maximum difference of 2%, for SCMH1
and CACYBP the biggest differences were 22% between
CD19+ B cells and CD4+ T cells and 13% for CD19+ B
cells and neutrophils, respectively. This comparison
strongly suggests that the observed loss of DNA methyla-
tion found in individuals with KDM5C mutations are not
due to differences in the proportion of blood cell types.
DNA methylation patterns at FBXL5, SCMH1 and CACYBP
promoters in general population
In our discovery dataset of 10 KDM5C mutations cases
and 19 controls, we observed no overlap in DNA methyla-
tion levels between cases and controls for three genes
FBXL5, SCMH1 and CACYBP. We wanted to test the fre-
quency of loss of DNA methylation in these three genes in
the general population. For these analyses we used 6 Illu-
mina Infinium HumanMethylation datasets of white blood
cells from GEO NCBI database, comprising a total 946
control samples passing QC (Additional file 1: Table S6).
Three datasets (GSE36064, GSE27097, GSE20236) [48,49]
investigated DNA methylation association with age and
included only control samples, while the other studies
investigated DNA methylation association with disease
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cancer (GSE19711) [27] and trisomy 21 (GSE25395) [50].
Due to common nature of diabetes we have included sam-
ples with this disease into our control dataset, but have
excluded ovarian cancer samples because cancer as well as
cancer therapies are known to alter epigenetic marks [51]
and somatic KDM5C mutation was previously identified
in cancer [52,53]; trisomy 21 cases were also excluded due
to overlapping ID phenotype with KDM5C mutations
cases [50]. None of the 946 control samples exhibited loss
of DNA methylation comparable with KDM5C mutations
cases (Figure 5).
We have also analyzed the association of DNA methyla-
tion levels at these sites with age, ethnicity, and sex for the
6 datasets. These data were analyzed separately within
each study to avoid possible batch effects. We did not ob-
serve any significant association of DNA methylation at
these three loci with ethnicity or age. There was a small
(median differences = 0.01-0.04) but highly significant in-
crease of DNA methylation in females compared to males
in FBXL5 and CACYBP (p < 1.00E-04) and a trend to-
wards significance for SCMH1 (p = 0.07), in the diabetes
study where samples of both sexes were included [27]
(Figure 6). We also assessed the consistency of the
observed sex-specific differences in 9 additional autosomal
CpG sites (top candidates with the largest DNA methyla-
tion loss, delta beta ≤ −0.2 from Table 1). Similar to diffe-
rences described for FBXL5, CACYBP and SCMH1, we
observed a significant (q-value ≤ 0.05) increase of DNA
methylation in females compared to males in 5 loci and a
trend towards significance (q-value ≤ 0.1) in three out of 9
tested loci with the delta beta differences ranging from
0.01 to 0.06 (Additional file 1: Table S7).
DNA methylation comparison at FBXL5, SCMH1 and
CACYBP between brain and blood
Since brain tissue from individuals with KDM5C muta-
tions is not available for study, we took an alternative
approach to assess whether the genomic targets we iden-
tified might be demonstrated to be functionally import-
ant in brain. In this regard, we investigated whether
DNA methylation levels in brain are similar to those in
blood and whether sex-specific DNA methylation
differences we found in blood are also observed in the
brain. For this analysis we used a published Illumina
HumanMethylation27 dataset for four brain regions
(temporal cortex, frontal cortex, cerebellum and pons)
of neurologically normal individuals (GEO Accession
No: GSE15745) [29]. DNA methylation at three tested
CpG sites exhibited overall hypermethylation (methyla-
tion level > 50%) in brain and blood for FBXL5 and
SCMH1 with the exception of cerebellum which had
intermediate methylation levels in brain (30-40%) and
high methylation levels in blood (70%). CACYBP hadintermediate levels of DNA methylation in both brain
and blood (30-50%) (Figure 6). Furthermore, we
observed a small but statistically significant increase of
DNA methylation in females compared to males in three
brain regions at FBXL5 and in four brain regions at
CACYBP, which was similar to sex-specific difference
found in blood (Figure 6, Additional file 1: Table S8). In
conclusion, these data suggest that DNA methylation at
FBXL5 and CACYBP can be regulated by similar
mechanisms in both blood and brain and the observed
sex- specific differences could be the result of differences
in KDM5C/KDM5D dosage between males and females.
DNA methylation levels at FBXL5, SCMH1 and CACYBP and
KDM5C/KDM5D dosage in blood
KDM5C is an X-linked gene that escapes X-inactivation
in humans and mouse [18,19,54], and has a functional
Y-linked homologue KDM5D [55]. Interestingly, in
mouse the degree of Kdm5c’s escape from X –inactiva-
tion is highly variable across different tissues. The level
of transcript from the inactive X allele is 20-70% of the
active X allele [56]. It is not known if the same variability
is present in humans. In mouse brain, Kdm5c/Kdm5d
are expressed in a sex-specific fashion i.e., the expression
of Kdm5c is significantly higher in female brains than in
male brains, and the expression of Kdm5d in males is
not sufficient to compensate for the female bias in
Kdm5c expression [21]. Furthermore, in human tissues,
KDM5D is reported to be expressed at lower levels than
KDM5C. However, as commercially available RNA
mixed from several individuals was used for this experi-
ment the proportion of male cells present in these sam-
ples is not known [3]. Our observation of increased
DNA methylation in females compared to males in the
top three affected loci (Figure 6), led us to hypothesize
that DNA methylation at these loci might depend on sex
chromosome dosage and specifically on the dosage of
the X and Y linked homologues, KDM5C and KDM5D,
respectively. To further investigate this, we assessed
FBXL5, SCMH1 and CACYBP DNA methylation levels
using targeted pyrosequencing assays in blood samples
with different sex chromosome constitutions and
reflecting variation in KDM5C/KDM5D dosage, includ-
ing 47,XXX (KDM5C/KDM5C/KDM5C, N = 3), 47,XXY
(KDM5C/KDM5C/KDM5D, N = 3), 46,XX (KDM5C/
KDM5C, N = 16), 46,XY (KDM5C/KDM5D, N = 19) and
45,X (KDM5C/0, N = 11) in comparison to males with
KDM5C mutations (0/KDM5D, N = 10) and female car-
riers of KDM5C mutation (KDM5C/0, N = 4). We found
that the DNA methylation levels at these three genes
generally correlated with KDM5C/KDM5D dosage for
all three genes analyzed (Figure 7). 47,XXX females
exhibited the highest DNA methylation closely followed
by 47, XXY males, 46,XX females and 46,XY males for
AB
C
Figure 5 DNA methylation at the three top significant CpGs in
KDM5C mutations cases and population controls. DNA
methylation microarray data at three CpG sites within CpG-rich
promoters of three genes FBXL5 (A), SCMH1 (B) and CACYBP (C) as
determined in 6 published studies using Illumina methylation27
array. AF (Aging in females, n = 93), AP1 (aging pediatric 1, n = 398),
AP2 (aging pediatric 2, n = 79), CO (cancer ovarian, n = 257), DB
(diabetes, n = 99), DS (Down syndrome, n = 21), K-C are controls
from our study (N = 16), K-M are KDM5C mutations cases. For CO
and DS only control samples were included.
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ferences for SCMH1 between 46,XX females and 46,XY
males suggesting that for this gene other factors might
be involved in equalizing DNA methylation between the
two sexes.
DNA methylation levels were similar for 45,X females
and female carriers of KDM5C mutations but significantly
lower than in the four groups described above. This sug-
gests that a single functional copy of KDM5C, without add-
itional activity from KDM5D, is not sufficient to achieve
levels of DNA methylation present in females and males
with normal karyotypes. Males with KDM5C mutations
exhibited the lowest DNA methylation of the 7 analyzed
groups. They had significantly lower DNA methylation than
females with only one functional copy of KDM5C (45,X
and KDM5C mutation female carriers) (Figure 7), suggest-
ing that KDM5D alone is not sufficient to compensate for
absence of functional the KDM5C.
The differences among groups with normal or extra
copies of KDM5C/KDM5D (the 47,XXX, 47, XXY, 46, XX
and 46, XY) were substantially smaller than the differences
for cases missing one copy of functional KDM5C (45, X,
females and males with KDM5C mutations). This could
be due to the fact that two copies of KDM5C or one copy
each of KDM5C and KDM5D is close to saturation of
H3K4 demethylase activity at target promoters. Another
possible explanation of small differences between 46, XX
females and 46, XY males observed in both brain and
blood, is that KDM5D is expressed only at slightly lower
levels than KDM5C from inactive X-chromosome in
human, making 46,XX and 46,XY relatively close in their
levels of H3K4 demethylase activity, in contrast to larger
differences between males with KDM5C mutation vs. 45,X
females, where the difference is between KDM5D and
KDM5C expressed from an active X. The observation that
KDM5C mutation female carriers exhibit DNA methyla-
tion levels similar to individuals with 45,X karyotype and
the fact these females have highly skewed X-chromosome
inactivation [5], suggests that in carriers the wild
type KDM5C is expressed from the preferentially active
X-chromosome.
Based on these data we suggest that DNA methylation
levels at FBXL5, SCMH1 and CACYBP promoters cor-
relate with H3K4 demethylase activity of the proteins
* *** **NS





Figure 6 Sex-specific DNA methylation differences in FBXL5, CACYBP and SCMH1 promoters in blood and four brain regions. Boxplots
show DNA methylation levels in three CpGs located in the promoters of FBXL5, CACYBP and SCMH1 in 99 (48 males/51 females) blood samples
(GSE20067), 133 (90 males/43 females) frontal cortex samples (FCTX), 127 (85 males/42 females) temporal cortex samples (TCTX), 121 (86 males/35
females) cerebellum samples (CBL) and 125 (87 males/38 females) pons samples from neurologically normal individuals (GSE15745). The Y axis
shows DNA methylation levels presented as C/C + T and ranging from 0 to 1. The bottom and the top of the box are 25th and 75th percentiles
respectively, the whiskers are within the 1.5 interquartile range (IQR) of the data, and the circles, are outlier data points above or below 1.5 IQR.
P-values were calculated using Kruskal-Wallis test. **** is p <0.0001, *** is p < 0.001, ** is p < 0.01, * is p < 0.05, NS is p > 0.1.
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H3K4 methylation and DNA methylation [22].
Discussion
Advances in molecular technologies have helped to identify
genetic causes in many cases of syndromic and non-
syndromic forms of intellectual disability (ID) [57-59].
However, the molecular pathogenesis of ID still remains in-
completely understood. It has been suggested based on
known genetic etiologies that perturbed neuronal homeo-
stasis altering synaptic outputs could be a key component
of the cognitive impairment phenotype [60]. This notion is
strongly supported by the types of functions attributable to
genes mutated in ID which include basic cellular functions,
such as transcription, translation, RNA biogenesis, protein
turnover, and cytoskeletal dynamics [60]. One important
emerging mechanism in ID is epigenetic dysregulation that
ultimately affects transcription of multiple genes [1,57].
KDM5C is one of more than 20 epigenetic regulators
involved in ID [1]. The identification of specific down-
stream targets exhibiting aberrant epigenetic marks in re-
sponse to mutation of an epigenetic regulator will have animportant impact on our understanding of the molecular
pathogenesis of ID.
Previously, profiling of mRNA in lymphoblastoid cell
lines of 12 males with KDM5C mutations compared to 5
controls identified 11 upregulated genes. These transcrip-
tional changes were not very consistent among KDM5C
mutations samples, and a combination of at least 6 genes
was required to distinguish cases from controls [15]. None
of these 11 genes exhibited DNA methylation changes in
our dataset. Thus, it is likely that these expression differ-
ences are more tissue and developmental stage specific,
than the DNA methylation patterns, potentially reflective
of disrupted binding of KDM5C specifically in lympho-
blastoid cell lines. DNA methylation patterns can be main-
tained by DNMT1 through replication and multiple cell
divisions [61], and thus if they occur early in development
they could be represented in multiple lineages including
peripheral blood, but not be reflective of gene expression
patterns in all differentiated lineages. This has, in fact,
been observed in neurodevelopmental syndromes such as
Immunodeficiency–centromeric instability–facial anomal-









KDM5C/KDM5D N of samples
1 XaXiXi No C/C/C 3
2 XaXiY No C/C/D 3
3 XaXi No C/C 16
4 XaY No C/D 19
5 XaXi Yes C 4
6 Xa0 No C 11
7 XaY Yes D 10
Figure 7 DNA methylation at FBXL5, SCMH1 and CACYBP promoters correlates with KDM5C/KDM5D dosage. Boxplots show DNA
methylation levels for CpG sites within the FBXL5, SCMH1 and CACYBP promoters in blood in 7 group of samples with different dosage of KDM5C/
KDM5D. CpG numbering corresponds to Figures 4D, 6D and 7D. CACYBP CpG#2 boxplot is not shown, as no correlation with KDM5C/KDM5D
dosage was found for this site. The Y axis is % of DNA methylation. The X axis shows groups of samples, numbered from 1 to 7. Information for
each group regarding sex chromosome constitution, X-chromosome inactivation (XCI, Xa is active and Xi is inactive X-chromosome respectively),
presence/absence of KDM5C mutation, functional KDM5C/KDM5D dosage, and number of samples is shown in the table beside the graph.
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of DNA methylation associated with KDM5C mutations,
coincided with an enhancer mark H3K4me1 in ES and
lymphoblastoid cell lines. In contrast, DNA sequences
more proximal to the TSS were hypomethylated in both
controls and cases and coincided with the active promoter
mark H3K4me3 (Figure 4, Additional file 2: Figures S6-S9)
[39]. These data suggest that regions affected by loss of
DNA methylation have enhancer-driven rather than basal
promoter function. As enhancers are involved in the con-
trol of spatial and temporal gene expression [63], the rela-
tionship between loss of DNA methylation at identified
sites and expression at downstream genes is likely to be
more complex than a simple inverse correlation.
The mechanism of the observed loss of DNA methyla-
tion associated with loss of function mutations in KDM5C
is not completely clear; however, it is unlikely to be the di-
rect consequence of loss of KDM5C function, as KDM5C
is not known to possess DNA methyltransferase activity.Based on the current literature, the most plausible mecha-
nism is that a deficiency in H3K4 demethylase activity
leads to increased H3K4 methylation, which protects DNA
from de novo DNA methylation at KDM5C downstream
target loci. In mouse ES cell, Dnmt3L recruits de novo
methyltransferases to DNA associated with unmethylated
forms of H3K4, and contact between Dnmt3L and the nu-
cleosome is inhibited by all forms of H3K4 methylation
[26]. Biochemical assays have shown that the human de
novo methyltransferase DNMT3A interacts with histone
H3 unmethylated at K4, whereas di- and tri-methylation
inhibit this interaction [64]. There is also evidence from a
yeast model system lacking endogenous DNA methyltrans-
ferases and ectopically expressing mouse Dnmt3a and
Dnmt3L that depletion of H3K4 methylation results in
increased DNA methylation [65]. In humans, a correlation
of increased tri-methylation in H3K4 with reduced DNA
methylation at promoters has been shown in fibroblast
cells from normal individuals [66].
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tions in individuals with mutations in the KDM5C
gene further support the link between H3K4 methyla-
tion and DNA methylation. These data show, for the
first time, a functional consequence of loss of func-
tion of H3K4 demethylase resulting in significant
alterations of DNA methylation at specific gene tar-
gets at a genome-wide level. Furthermore, in agree-
ment with cross-talk of H3K4 methylation and DNA
methylation, there was significantly more loss than
gain of DNA methylation resulting from mutations in
KDM5C. In mammals several H3K4 demethylases
have been described. Apart from four enzymes of the
KDM5 family, KDM1A and B specifically act to
demethylate di- and mono-methylated forms of H3K4,
and KDM2B similarly to the KDM5 family specifically
demethylates tri- and di-methylated forms of H3K4
[67,68]. At this point it is not clear if the loss of
DNA methylation associated with KDM5C mutations
is specific to KDM5C loss of function or would also
be observed in the context of loss of function of
other H3K4 demethylases. In support of the concept
that loss of DNA methylation could be a common as-
sociation of loss of H3K4 demethylase activity, mouse
oocytes deficient in the H3K4 demethylase Kdm1b
demonstrated a global increase in H3K4 di-
methylation and failed to generate normal DNA
methylation marks at several imprinted loci [68].
However, as we did not observe loss of DNA methy-
lation at imprinted genes in patients with KDM5C
mutations, the genomic sites demonstrating loss of
DNA methylation for each H3K4 demethylase are
likely to be specific, possibly reflecting the binding
sites of these proteins.
Further support for the inter-dependence of histone
methylation and DNA methylation in humans comes
from cancer research. Mutations in IDH1 and IDH2,
frequently found in gliomas and acute myeloid leuke-
mias (AML), are characterized by enzymatic gain of
function and subsequent production of hydroxygluta-
rate, which inhibits several histone demethylases, in-
cluding H3K9, H3K27, H3K36 and H3K4 [69]. The
somatic mutations in IDH1/IDH2 are associated with
genome-wide hypermethylation in AML compared ei-
ther to normal bone marrow or to AML caused by
mutations in other genes. However at this point it is
not clear which specific histone marks contribute dir-
ectly to this DNA hypermethylation phenotype [70].
Interestingly, two genes, PABPN1 and ZNF532, dem-
onstrating loss of DNA methylation in our study
(Additional file 1: Table S4) were found to be hyper-
methylated in AML with IDH1 mutation [70]. These
data suggest that there could be some common
mechanism regulating DNA methylation of these twogenes in opposite directions in the context of loss of
function of KDM5C and gain of function of IDH1.
The genes FBXL5, SCMH1 and CACYBP on which we
focused in our downstream analysis have exhibited a
surprisingly large degree of DNA methylation differences
between cases and controls reminiscent of the DNA
methylation alterations at imprinted loci in disorders
affecting neurodevelopment, such as Prader-Willi and
Angelman syndromes [71,72]. Further, loss of DNA
methylation at these sites was not observed in 946 popu-
lation control blood samples from publically available
datasets, suggesting that altered DNA methylation at
these three genes could be used for establishing patho-
logical authenticity of new missense mutations, as in
silico predictions of effects on protein function are often
inconclusive, and functional experiments are expensive
and labor intensive. Thus, as KDM5C mutation cases
are frequently indistinguishable from other genetic
causes of ID based on clinical phenotype alone [15],
DNA methylation analysis could complement KDM5C
sequencing to provide more accurate molecular diagno-
sis leading to improved patient management.
Interestingly, the three top candidate genes are part of
ubiquitin-ligase protein degradation pathways. Synaptic
network remodeling, a vital part of central nervous sys-
tem function, depends on ubiquitin-mediated protein
degradation at the postsynaptic membrane [73]. Genes
involved in ubiquitination pathways have already been
implicated in a number of other neurodevelopmental
disorders, such as Angelman syndrome (loss of function
of maternal copy of UBE3A) [71], and autism (copy
number variants in PARK2, RFWD2, FBX040) [74]. Fur-
thermore, 7% of XLID genes identified to date are compo-
nents of the ubiquitin pathway [75].
We have shown that these three genes are ubiquitously
expressed in human tissues at relatively low levels com-
pared to the house-keeping gene GAPDH. Although it is
currently not clear how loss of DNA methylation at these
sites affect gene expression, we propose that abnormal ex-
pression of these genes at specific cell types/developmen-
tal stages causes disturbances in downstream pathways
such as degradation of target proteins. FBXL5 has been re-
cently discovered to be a component of an E3 ubiquitin
ligase complex that targets IRP2, an iron regulatory pro-
tein 2 important in intracellular and plasma iron homeo-
stasis [43,76]. IRP2 regulates RNA stability and translation
by binding to iron responsive - RNA stem loop structures,
in a number of genes involved in iron uptake, storage and
utilization [44]. While FBXL5 loss of function leads to em-
bryonic lethality in Fbxl5−/− mice, associated with aber-
rant iron accumulation and increased oxidative stress [77],
Irp2 −/− knockout mice exhibit a neurological phenotype
associated with locomotor abnormalities accompanied by
iron accumulation in white and grey matter [78]. Thus,
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iron accumulation, thereby contributing to seizures and/
or ID phenotypes observed in males with KDM5C muta-
tions. SCMH1 is a member of the Polycomb-group 1
complex, which not only is a transcriptional repressor, but
also acts as an E3 ubiquitin ligase for the geminin protein
involved in DNA replication and maintenance of undiffer-
entiated cellular states. Specifically, SCMH1 has been
shown to provide an interaction domain for geminin [42].
Recently a genome-wide association study implicated
SCMH1 in the regulation of human height [79], thus it is
possible that loss of DNA methylation at SCMH1 is im-
portant for short stature associated with KDM5C muta-
tions. CACYBP (Sip) is part of the SCF-like complex,
involved in ubiquitin-mediated degradation of the
transcriptional activator β-catenin [40,41]. β-catenin is a
signaling molecule playing an important role in
neurodevelopmental processes such as neural crest devel-
opment, development of cortical and hippocampal neuro-
epithelium, and dendrite spine morphogenesis [80-82]. In
addition, it has been implicated in seizure susceptibility
[83]. Further, CACYBP was shown to dephosphorylate
ERK1/2 [84], extracellular signal-regulated kinases, im-
portant in many aspects of early brain development and
implicated in 16p11.2 and 22q11 deletion syndromes phe-
notypes [85].
As the described DNA methylation changes in our
study were identified in blood samples, an important
question that cannot be directly addressed by our data is
the issue of whether parallel changes occur in brain. As
de novo DNA methylation is an important process in
epigenetic reprogramming occurring at early stages of
embryonic development [22,86], we suggest that loss of
DNA methylation in the blood of patients with KDM5C
mutations could at least in part result from abnormally
high H3K4 di/trimethylation in the embryo, protecting
DNA from de novo methylation. We expect that this
state is maintained through differentiation into multiple
lineages. In support of this, we found parallel sex-
specific DNA methylation differences in both brain and
blood at FBXL5 and CACYBP, whereas SCMH1 exhib-
ited this difference only in blood, but not in brain. We
suspect that these observed sex-specific differences are
due to KDM5C/KDM5D dosage rather than the effects
of sex hormones, as the DNA methylation at tested tar-
gets correlates better with sex chromosome constitution
than with gonadal sex, e.g. the highest DNA methylation
was observed in 47,XXX females, followed by 47,XXY
males, 46,XX females, 46,XY males, 45,X females. The
lowest DNA methylation is seen in males with KDM5C
mutations (Figure 7). In addition we observed that fe-
male carriers of KDM5C mutations have DNA methyla-
tion levels similar to 45,X females, reflecting the fact
that they have only one functional copy of KDM5C.Based on DNA methylation comparison between brain
and blood, we propose that the epigenetic status of
FBXL5 and CACYBP is regulated by KDM5C in both
brain and blood, and that their deregulation in brain can
contribute to the intellectual disability and seizure phe-
notypes in individuals with KDM5C mutation. We
propose as well that KDM5C contributes to sex-specific
differences in brain function. In contrast, SCMH1 might
be responsible for other aspects of the clinical phenotype
associated with KDM5C mutation such as growth abnor-
malities. Furthermore, the KDM5C-mutation associated
targets identified here could play a role in Turner syn-
drome. It has been previously suggested that X-linked
genes escaping X-inactivation such as KDM5C are likely
to be implicated in neurocognitive phenotypes of 45,X
females with Turner syndrome, who in spite of normal
cognitive abilities, frequently have problems in spatial
reasoning and emotion recognition [87,88]. Our obser-
vation of loss of DNA methylation at the FBXL5,
SCMH1 and CACYBP promoters in 45, X females com-
pared to XX females and XY males, but to a lesser de-
gree than in males with KDM5C mutations, supports
this hypothesis and suggests that deregulation of epigen-
etic targets of KDM5C could be relevant to the mild
neurodevelopmental impairments found in females with
Turner syndrome. Similarly, loss of DNA methylation at
these three genes found in female carriers of KDM5C
mutations could contribute to learning difficulties fre-
quently observed in such individuals [5,7].
In summary these data provide new opportunities to
address the molecular basis, both genetic and epigenetic,
of ID. An important area for future investigation would
be to establish both spatial (tissue-specific) and temporal
(developmental stage- specific) maps of KDM5C targets,
and to annotate how loss of KDM5C function impacts
expression of these targets through embryonic develop-
ment and in diverse tissues. Validation of the affected
molecular pathways, described here such as abnormal
iron homeostasis or β-catenin dysregulation could also,
in an animal model of KDM5C mutations, provide a
framework for potential therapeutic developments for
patients with KDM5C mutations.
Conclusions
We have, for the first time, identified significant multilo-
cus loss of DNA methylation in individuals with loss of
function mutations of a gene encoding histone modify-
ing enzyme, specifically a histone H3K4 demethylase
KDM5C. We have validated changes in three loci with
the most prominent changes: FBXL5, SCMH1 and
CACYBP. We have also demonstrated that loss of DNA
methylation at these three genes is specifically associated
with KDM5C mutations and is not observed in >900
control blood samples. In addition we have shown that
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http://www.biomedcentral.com/1755-8794/6/1DNA methylation at these three genes correlates with
dosage of KDM5C and its Y-linked homologue KDM5D
in blood of individuals with different sex chromosome
complements. Finally we observed parallel sex-specific
differences in several brain regions for FBXL5 and
CACYBP, suggesting that these genes could play an im-
portant role in the ID phenotype of individuals with
KDM5C mutations.
Additional files
Additional file 1: Table S1. Clinical features and demographic
information of the 10 male patients with X-linked intellectual disability
due to KDM5C mutations, 2 male patients with a variant of unknown
significance. Table S2: Primer Sequences. Table S3: Number of
significant CpG sites with loss and gain of DNA methylation detected by
multivariate permutation analysis for different levels of confidence (1-α)
and false discovery proportion limit (γ). Table S4: The top 53 most
significant CpG sites that are differentially methylated between the
KDM5C mutations and normal controls with the lowest FDP = 0 and the
highest confidence level of 99.5%. Table S5: The top 53 most significant
CpG sites with additional CpG sites within the same genes. Table S6:
GEO studies used to assess DNA methylation at at FBXL5, SCMH1 and
CACYBP in blood samples of population controls. Table S7: Analysis of
sex specific DNA methylation differences in blood samples from diabetes
study (GSE20067). Table S8: Analysis of sex specific DNA methylation
differences in brain in FBXL5, SCMH1 and CACYBP promoters.
Additional file 2: Figure S1. Scatter plots of DNA methylation
determined by Illumina (X-axis) and pyrosequencing (Y-axis) at
overlapping CpG sites. Grey diamonds are cases with KDM5C mutations,
black squares are controls and grey triangles are individuals with
p.R1546Q variant. Figure S2: Visual mapping of all 31 samples to the
coordinate space defined by the first two principal components reveals
that there is no clear separation between samples with and without
KDM5C mutations. The principal component analysis (PCA) was
performed using all 23,837 CpG sites. The red dots represent the 10
mutation cases, the 19 light green dots represent controls and the two
dark green dots represent the benign mutation variants (p.R1546Q).
Figure S3: Unsupervised hierarchical clustering of methylation data at 23,
837 CpG sites reveals that there is no clear separation between samples
with and without KDM5C mutations. C1-16, are unrelated controls, UN-
R1-2 are unaffected relative. R1546Q 1–2 are cases with benign variant,
and the rest of the samples are KDM5C mutation cases. Figure S4: Visual
mapping of all 31 samples to the coordinate space defined by the first
two principal components. The principal component analysis (PCA) was
performed using only the methylation levels at the 53 most significant
CpG sites (the same CpG sites as shown in Figure 1). The red dots
represent the 10 KDM5C mutation cases, the 19 light green dots
represent controls, and the two dark green dots represent the benign
mutation variants (p.R1546Q). Although the PCA procedure did not use
any information on the mutation status, the data distribution shows a
clear separation between aberrant mutations and benign mutations and
controls. Figure S5: DNA methylation levels at 3 CpG sites in promoter
of Long Interspersed Element-1 (LINE-1) as determined by
pyrosequencing. The Y-axis is DNA methylation%. Two groups of
samples, controls (C; N = 19) and KDM5C mutation cases (K;N = 10) are
shown on the X-axis. Figure S6: Regional DNA methylation in SCMH1
promoter. A) Screenshot from the UCSC genome browser showing
location of SCMH1 promoter exon1, intron1, CpG island, Illumina 27 K
microarray probes and pyrosequencing assays and tracks for H3K4me1
and H3K4me3 in lymphoblastoid cell line (GM12878) and ES cell line
(H1 h-ES) (Broad Institute Histone data). B&C) Boxplots of Illumina DNA
methylation data for two microrray probes within SCMH1 gene. The Y
axis shows DNA methylation levels presented as C/C + T and ranging
from 0 to 1. The bottom and the top of the box are 25th and 75th
percentiles respectively, the whiskers are within the 1.5 interquartile
range (IQR) of the data, and the circles, are outlier data points above orbelow 1.5 IQR. C are controls (N = 19), K are cases with KDM5C mutations
(N = 10), V are cases with p.R1546Q sequence variant. D) DNA
methylation upstream of SCMH1 transcription start site as determined by
pyrosequencing assay (pyro). The order of CpG sites are shown from the
further upstream towards the transcription start site. Each column is an
average for each of three groups of 1)10 cases with KDM5C mutations
(mutation), 2)19 controls (control), and 3) two individuals with the p.
R1546Q variant of unknown clinical significance (VUS). The arrows show
the CpG sites from the microarray. P-values were determined by Kruskal-
Wallis test between mutation cases and controls. Figure S7: Regional
DNA methylation in CACYBP promoter. A) Screenshot from the UCSC
genome browser showing location of CACYBP promoter, exons1&2,
introns 1&2, CpG island, Illumina 27 K microarray probes and
pyrosequencing assays and tracks for H3K4me1 and H3K4me3 in
lymphoblastoid cell line (GM12878) and ES cell line (H1 h-ES) (Broad
Institute Histone data). B&C) Boxplots of Illumina DNA methylation data
for two microrray probes within CACYBP gene. The Y axis shows DNA
methylation levels presented as C/C + T and ranging from 0 to 1. The
bottom and the top of the box are 25th and 75th percentiles
respectively, the whiskers are within the 1.5 interquartile range (IQR) of
the data, and the circles, are outlier data points above or below 1.5 IQR.
C are controls (N = 19), K are cases with KDM5C mutations (N = 10), V are
cases with p.R1546Q sequence variant. D) DNA methylation upstream of
CACYBP transcription start site as determined by pyrosequencing assay
(pyro). The order of CpG sites are shown from the further upstream
towards the transcription start site. Each column is an average for each of
three groups of 1)10 cases with KDM5C mutations (mutation), 2)19
controls (control), and 3) two individuals with the p.R1546Q variant of
unknown significance (VUS). P-values were determined by Kruskal-Wallis
test between mutation cases and controls. **** is p <0.0001, * is p <0.05.
Figure S8: Regional DNA methylation in ZMYMD12/PPCS promoter. A)
Screenshot from the UCSC genome browser showing location of
ZMYND12 and PPCS promoter, CpG island, Illumina 27 K microarray
probes and pyrosequencing assays and tracks for H3K4me1 and
H3K4me3 in lymphoblastoid cell line (GM12878) and ES cell line (H1 h-ES)
(Broad Institute Histone data). B&C) Boxplots of Illumina DNA methylation
data for two microrray probes within ZMYND12 gene. The Y axis shows
DNA methylation levels presented as C/C + T and ranging from 0 to 1.
The bottom and the top of the box are 25th and 75th percentiles
respectively, the whiskers are within the 1.5 interquartile range (IQR) of
the data, and the circles, are outlier data points above or below 1.5 IQR.
C are controls (N = 19), K are cases with KDM5C mutations (N = 10), V are
cases with p.R1546Q sequence variant. D) DNA methylation upstream of
PPCS transcription start site and within exon1/intrion1 of ZMYND12 as
determined by pyrosequencing assay (pyro). The order of CpG sites are
shown from the further upstream towards the PPCS transcription start
site. Each column is an average for each of three groups of 1)10 cases
with KDM5C mutations (mutation), 2)19 controls (control), and 3) two
individuals with the p.R1546Q variant of unknown significance (VUS). P-
values were determined by Kruskal-Wallis test between mutation cases
and controls. **** is p <0.0001. Figure S9: Regional DNA methylation in
DYDC1/DYDC2 promoter. A) Screenshot from the UCSC genome browser
showing location of DYDC1/DYDC2 promoter, CpG island, Illumina 27 K
microarray probes and pyrosequencing assays and tracks for H3K4me1
and H3K4me3 in lymphoblastoid cell line (GM12878) and ES cell line
(H1 h-ES) (Broad Institute Histone data). B&C) Boxplots of Illumina DNA
methylation data for two microrray probes within DYDC1 gene. The Y
axis shows DNA methylation levels presented as C/C + T and ranging
from 0 to 1. The bottom and the top of the box are 25th and 75th
percentiles respectively, the whiskers are within the 1.5 interquartile
range (IQR) of the data, and the circles, are outlier data points above or
below 1.5 IQR. C are controls (N = 19), K are cases with KDM5C mutations
(N = 10), V are cases with p.R1546Q sequence variant. D) DNA
methylation upstream of DYDC1 transcription start site as determined by
pyrosequencing assay (pyro) overlapping Illumina CpG site cg17703212.
Column is an average for each of three groups of 1)10 cases with KDM5C
mutations (mutation), 2)19 controls (control), and 3) two individuals with
the p.R1546Q variant of uknown significance (VUS). P-values were
determined by Kruskal-Wallis test between mutation cases and controls.
**** is p <0.0001. Figure S10: Expression of FBXL5, SCMH1 and CACYBP in
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http://www.biomedcentral.com/1755-8794/6/1a panel of human tissues: BT -brain total, FB- fetal brain, CC-cerebral
cortex, CB-cerebellum, TL- temporal lobe, FL –frontal lobe, SC –spinal
cord, K-kidney, H-heart, L-liver, SM-smooth muscle, SK-skeletal muscle,
LCL-lymphoblastoid cell line. Error bars are standard deviation of
duplicated q-PCR experiments. Figure S11: DNA methylation levels of
three CpG sites cg02630888 (FBXL5), cg03387723 (SCMH1), cg16743289
(CACYBP) in different blood cell types (GSE35069). The cell types are
whole blood, peripheral blood mononuclear cells (PBMC), granulocytes
and seven isolated cell populations (CD4+ T cells, CD8+ T cells, CD56+
NK cells, CD19+ B cells, CD14+ monocytes, neutrophils (Neu), and
eosinophils (Eos)) which are each shown by different colour. Y-axis is
beta methylation value determined by Illumina methylation450 array
(GSE35069). Each column represents mean methylation from 6 samples
from healthy males, error bars are standard deviation from the mean.
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